These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1972843)

  • 21. A novel regimen of vorinostat with interferon gamma for refractory Sézary syndrome.
    Gardner JM; Introcaso CE; Nasta SD; Kim EJ; Vittorio CC; Rook AH
    J Am Acad Dermatol; 2009 Jul; 61(1):112-6. PubMed ID: 19539845
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sézary syndrome, cutaneous T-cell lymphoma, and extracorporeal photopheresis.
    Edelson RL
    Arch Dermatol; 1999 May; 135(5):600-1. PubMed ID: 10328207
    [No Abstract]   [Full Text] [Related]  

  • 23. New and established treatment options for mycosis fungoides and Sézary syndrome - an update.
    Dugas-Breit S; Schulze HJ; Hallermann C
    J Dtsch Dermatol Ges; 2014 Jul; 12(7):561-9. PubMed ID: 24889480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Painful ischemia of the extremities with T-cell lymphoma].
    Distelrath K; Neuber K; Blödorn-Schlicht N; Altenhoff J; Dührsen U; Düring J; Steinkraus V
    Hautarzt; 1999 Apr; 50(4):284-7. PubMed ID: 10354922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete molecular remission during biologic response modifier therapy for Sézary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity.
    Yoo EK; Cassin M; Lessin SR; Rook AH
    J Am Acad Dermatol; 2001 Aug; 45(2):208-16. PubMed ID: 11464181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cutaneous presentation of prolymphocytic leukaemia.
    Logan RA; Smith NP
    Br J Dermatol; 1988 Apr; 118(4):553-8. PubMed ID: 3259891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alemtuzumab in refractory Sézary syndrome.
    Reifs CM; Salido-Vallejo R; Garnacho-Saucedo GM; Corte-Sánchez S; González-Menchen A; García-Nieto AV
    An Bras Dermatol; 2016; 91(5):642-644. PubMed ID: 27828640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deoxycoformycin in the treatment of mature T-cell leukaemias.
    Dearden C; Matutes E; Catovsky D
    Br J Cancer; 1991 Nov; 64(5):903-6. PubMed ID: 1931613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteonecrosis of the Jaw in Association With Chemotherapy in the Setting of Cutaneous T-Cell Lymphoma.
    DeSesa CR; Appugounder S; Haberland C; Johnson MP
    J Oral Maxillofac Surg; 2016 Feb; 74(2):292-301. PubMed ID: 26296596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sézary syndrome and seronegative polyarthritis: treatment with extracorporeal photochemotherapy.
    Macheiner W; Jantschitsch C; Graninger W; Pálóczy K; Bálint G; Marschalkó M; Kainberger F; Breier F; Knobler RM
    J Am Acad Dermatol; 2003 Feb; 48(2):220-6. PubMed ID: 12582392
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mogamulizumab-induced vitiligo in patients with Sézary syndrome: three cases.
    Algarni AS; Ram-Wolff C; Bagot M; De Masson A
    Eur J Dermatol; 2021 Apr; 31(2):213-216. PubMed ID: 33814357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H).
    Gautschi O; Blumenthal N; Streit M; Solenthaler M; Hunziker T; Zenhäusern R
    Eur J Haematol; 2004 Jan; 72(1):61-3. PubMed ID: 14962265
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Retinoids in cutaneous T cell lymphomas.
    Mahrle G; Thiele B
    Dermatologica; 1987; 175 Suppl 1():145-50. PubMed ID: 3500880
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid onset of CD8+ aggressive T-cell lymphoma during bexarotene therapy in a patient with Sézary syndrome.
    Kreuter A; Altmeyer P
    J Am Acad Dermatol; 2005 Dec; 53(6):1093-5. PubMed ID: 16310082
    [No Abstract]   [Full Text] [Related]  

  • 35. [Sézary syndrome with ascitis: case report and review of the literature].
    Nubourgh I; Van den Broeck K; Bradstreet C; Praet JP; Cantinieaux B
    Rev Med Brux; 2005; 26(5):445-50. PubMed ID: 16318098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New developments in Sézary syndrome].
    Caudron A; Marie-Cardine A; Bensussan A; Bagot M
    Ann Dermatol Venereol; 2012 Jan; 139(1):31-40. PubMed ID: 22225740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.
    Janiga J; Kentley J; Nabhan C; Abdulla F
    Leuk Lymphoma; 2018 Mar; 59(3):562-577. PubMed ID: 29308723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel treatment of Sézary-like syndrome due to adult T-cell leukaemia/lymphoma with daclizumab (humanized anti-interleukin-2 receptor alpha antibody).
    Osborne GE; Pagliuca A; Ho A; du Vivier AW
    Br J Dermatol; 2006 Sep; 155(3):617-20. PubMed ID: 16911291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A case of pre-Sézary syndrome preceded by hand lesions.
    Lee NH; Lee SW; Choi EH; Lee WS; Ahn SK
    J Dermatol; 1999 Jul; 26(7):465-8. PubMed ID: 10458089
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II study of teniposide (VM26) in cutaneous T-cell lymphomas.
    Sorio R; Tirelli U; Zagonel V; Carbone A; Monfardini S
    Am J Clin Oncol; 1990 Feb; 13(1):14-6. PubMed ID: 2305716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.